Riik: Iisrael
keel: inglise
Allikas: Ministry of Health
INSULIN LISPRO
ELI LILLY ISRAEL LTD, ISRAEL
A10AB04
SOLUTION FOR INJECTION
INSULIN LISPRO 100 U/ML
S.C, I.V, I.M
Required
LILLY FRANCE S.A.S., FRANCE
INSULIN LISPRO
INSULIN LISPRO
Humalog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilization of diabetes mellitus.
2021-07-31
I HUMAVL A 06 Page 1 of 7 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed by a physician’s prescription only HUMALOG SOLUTION FOR INJECTION IN A VIAL THE ACTIVE INGREDIENT: insulin lispro 100 units/ml INACTIVE INGREDIENTS AND ALLERGENS: see chapter 2, section “Important information about some of the ingredients of this medicine” and chapter 6 “Additional information”. READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE. This leaflet contains concise in- formation about this medicine. If you have any further questions, please contact your doctor or pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar. 1. WHAT IS THIS MEDICINE INTENDED FOR ? HUMALOG is used for the treatment of adults and children who have diabetes and need insulin in order to maintain a balance of blood sugar levels. THERAPEUTIC GROUP: Rapid-acting insulins and insulin analogs. HUMALOG is used to treat diabetes. HUMALOG works more quickly than normal human insulin be- cause the insulin molecule has been changed slightly. You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood. HUMALOG is a substitute for your own insulin and is used to control glucose in the long term. It works very quickly and lasts a shorter time than soluble insulin (2 to 5 hours). You should normally use HUMALOG within 15 minutes of a meal (either before or after). Your doctor may tell you to use HUMALOG as well as a longer-acting insulin. Each kind of insulin comes with another patient information leaflet to tell you about it. Do not change your insulin un- less your doctor tells you to. Be very careful if you do change insulin. HUMALOG is suitable for use in adults and children. HUMALOG may be used in children when an advantage is expected compared to soluble insulin, for example, in the timing of injection in rela- tion to Lugege kogu dokumenti
X HUMA CTVL SF A 10 draft2 Page 1 of 11 HUMALOG 1. NAME OF THE MEDICINAL PRODUCT Humalog 100 units/ml, solution for injection in vial Humalog 100 units/ml, solution for injection in cartridge. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 units of insulin lispro* (equivalent to 3.5 mg). Vial Each vial contains 1,000 units insulin lispro in 10 ml solution. Cartridge Each cartridge contains 300 units of insulin lispro in 3 ml solution. *produced in _E.coli_ by recombinant DNA technology. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dose should be determined by the physician, according to the requirement of the patient. Humalog may be given shortly before meals. When necessary Humalog can be given soon after meals. Humalog takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously as compared with soluble insulin. This rapid onset of activity allows a Humalog injection (or, in the case of administration by continuous subcutaneous infusion, a Humalog bolus) to be given very close to mealtime. The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. The faster onset of action compared to soluble human insulin is maintained regardless of injection site. As with all insulin preparations, the duration of action of Humalog is dependent on dose, site of injection, blood supply, temperature, and physical activity. Humalog can be used in conjunction with a longer-acting insulin or oral sulphonylurea agents, on the advice of a physician. _Special populations _ _ _ X HUMA CTVL SF A 10 draft2 Page Lugege kogu dokumenti